Study: Link between diabetes drugs, pancreatic cancer risk unclear
NEW YORK — A new study published in the American Journal of Gastroenterology examined the possible link between pancreatic cancer and drugs designed to treat diabetes, and found the association to be unclear.
Researchers conducted a case-control study based on the British-based General Practice Research Database, which included drug prescriptions, diagnostics, hospitalizations and fatality information. The researchers also took into consideration such factors as body mass index, smoking, alcohol consumption and diabetes duration.
After examining 2,763 case patients that had a recorded diagnosis of pancreatic cancer, the researchers found that long-term use of metformin was associated with a decreased risk of pancreatic cancer only in women. Meanwhile, use of sulfonylureas and of insulin were associated with an increased risk of pancreatic cancer, they noted.
Click here for the full study.
Pfizer recalls 28 lots of branded, generic oral contraceptive
NEW YORK — A possible pill mix-up has prompted Pfizer to recall more than two dozen lots of a prescription contraceptive drug, the drug maker said.
Pfizer announced the voluntary nationwide recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 additional lots of the drug’s generic version. Pfizer manufactured and packaged the drugs, while Akrimax Pharmaceuticals commercialized them, and they were sold under the Akrimax brand.
The company said an investigation found that some blister packs of the drugs may contain an inexact count of inert or active ingredient tablets and that the tablets may not be in the correct sequence. The packaging error could leave women without adequate contraception and put them at risk of unintended pregnancy, the company said.
Lilly Diabetes donates diabetes camp scholarships
INDIANAPOLIS and ALEXANDRIA, Va. — Through a collaboration with the American Diabetes Association, the diabetes division of drug maker Eli Lilly has committed to send 89 children to diabetes camp this summer.
Lilly Diabetes said it donated the camp scholarships — a fund totaling $89,000 — to the American Diabetes Association’s 2012 camp scholarship fund. More than 400 diabetes camping programs exist worldwide serving approximately 30,000 youth with diabetes and their families, Lilly Diabetes said.
"Diabetes camps provide education on diabetes management and personal development that often lead to newfound confidence for many campers. Campers who may not have taken charge of their care before, can begin to feel empowered and eager to learn more about their own health and well-being," Lilly Diabetes VP Steve Sugino said. "Invaluable experiences like these are just a few of the many reasons that Lilly Diabetes supports diabetes camps through our collaboration with the American Diabetes Association."